Enforcement Report - Week Of June 01, 2022
NPPA fixes retail prices of 21 formulations under DPCO 2013
NPPA fixes retail prices of 21 formulations under DPCO 2013
Exela Pharma's Generic Folic Acid Receives Approval in US
In its decision in a consolidated appeal, Eli Lilly & Co. v. Hospira, Inc. and Eli Lilly & Co. v. Dr. Reddy's Laboratories, Ltd., the Federal Circuit had the occasion to apply the Supreme Court's distinction regarding the limits of prosecution history estoppel on the doctrine of equivalents, regarding the effects on the estoppel of amendments made that are only tangentially related to patentability. In this case, this doctrine salvaged a decision in favor of the patentee Eli Lilly in both cases, keeping generic versions of Lilly's patented drug from FDA approval until Lilly's Orange Book-listed patent have expired.
The national drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 22 formulations under Drugs Prices Control Order (DPCO), 2013 in related notification dated May 02, 2019.
Invatech Pharma`s Generic Folic Acid Receives Approval in US
Enforcement Report - Week of May 24, 2017
Vitalah® is committed to providing the highest quality dietary supplements, and part of that commitment is ensuring that each formulation includes the safest, most efficacious ingredients on the market. That's why Vitalah recently made three upgrades to its Adult Oxylent® formula: switching the source of folate from folic acid to 5-MTHF (5-methyltetrahydrofolate); changing the source of iodine from potassium iodide to kelp; and adding in sources of vitamins A and E.